Market
BSE Prices delayed by 5 minutes... << Prices as on Oct 01, 2026 - 3:59PM >>  ABB India  6854.4 [ 1.49% ] ACC  1182.2 [ -1.86% ] Ambuja Cements  363 [ -2.46% ] Asian Paints  2406.25 [ -0.29% ] Axis Bank  1214 [ -0.98% ] Bajaj Auto  10069.85 [ -7.28% ] Bank of Baroda  231.75 [ 0.32% ] Bharti Airtel  1741 [ -0.98% ] Bharat Heavy  422 [ 1.69% ] Bharat Petroleum  301 [ -0.66% ] Britannia Industries  4794.85 [ -0.33% ] Cipla  1346.85 [ -0.23% ] Coal India  421.5 [ -0.67% ] Colgate Palm  1735 [ -2.20% ] Dabur India  377 [ -1.05% ] DLF  662.6 [ -1.40% ] Dr. Reddy's Lab.  1200.1 [ -2.90% ] GAIL (India)  170.8 [ 0.06% ] Grasim Industries  2971.85 [ -3.12% ] HCL Technologies  1246 [ 1.38% ] HDFC Bank  719.35 [ 1.36% ] Hero MotoCorp  5173 [ -1.22% ] Hindustan Unilever  1841 [ -2.17% ] Hindalco Industries  944.4 [ 0.22% ] ICICI Bank  1305.5 [ -1.29% ] Indian Hotels Co.  716.15 [ -1.76% ] IndusInd Bank  880 [ -1.97% ] Infosys  1035 [ 4.02% ] ITC  257 [ -2.56% ] Jindal Steel  1099 [ -2.92% ] Kotak Mahindra Bank  419.8 [ 0.53% ] L&T  3685.5 [ -1.85% ] Lupin  2029 [ -0.64% ] Mahi. & Mahi  2851.05 [ -3.27% ] Maruti Suzuki India  11400 [ -4.59% ] MTNL  24.7 [ 7.30% ] Nestle India  1303.8 [ -0.63% ] NIIT  85.25 [ -0.70% ] NMDC  75 [ -2.33% ] NTPC  316.7 [ -1.65% ] ONGC  222.7 [ -1.02% ] Punj. NationlBak  109.9 [ -3.09% ] Power Grid Corpn.  254.65 [ -2.23% ] Reliance Industries  1166 [ -1.81% ] SBI  954 [ -0.70% ] Vedanta  251.9 [ -2.70% ] Shipping Corpn.  267.15 [ -1.24% ] Sun Pharmaceutical  1810 [ -0.55% ] Tata Chemicals  607.9 [ -0.54% ] Tata Consumer  949 [ -0.42% ] Tata Motors Passenge  280 [ -1.70% ] Tata Steel  179.1 [ -3.01% ] Tata Power Co.  350 [ -2.51% ] Tata Consult. Serv.  2079.3 [ 1.43% ] Tech Mahindra  1539 [ 0.40% ] UltraTech Cement  10799 [ -1.60% ] United Spirits  1338.2 [ -0.87% ] Wipro  159.5 [ 0.69% ] Zee Entertainment  71.9 [ -3.48% ] 
Hindustan Bio Sciences Ltd. Directors Report
Search Company 
You can view full text of the latest Director's Report for the company.
Market Cap. (Rs.) 7.53 Cr. P/BV 10.57 Book Value (Rs.) 0.70
52 Week High/Low (Rs.) 10/5 FV/ML 2/1 P/E(X) 0.00
Bookclosure 30/09/2024 EPS (Rs.) 0.00 Div Yield (%) 0.00
Year End :2025-03 

Your director's have pleasure in presenting the Directors' Report and the Audited Statement of
Accounts of the Company for the Financial Year ended 31st March 2025.

1. FINANCIAL SUMMARY/HIGHLIGHTS:

The performance of the Company during the year has been as under:

(Rs. in lakhs)

Particulars

2024-2025

2023-2024

Revenue from Operations

81.33

105.27

Other Income (Including Exceptional Items)

--

--

Total Expenses

71.51

100.00

Profit Before Tax

9.82

5.33

Less: Provision for Taxation

0.26

0.43

Profit / (Loss) After Tax

10.07

5.76

Other Comprehensive Income

--

--

Total Comprehensive Income

10.07

5.76

Earning per Equity Share-

0.10

0.06

Basic & Diluted (in Rs.)

REVIEW OF OPERATIONS/ STATE OF COMPANY’S AFFAIRS:

The total revenue of the Company for the Financial Year 2024-25 under review was Rs. 81.33 Lakhs
as against Rs.105.27 Lakhs for the Previous Financial Year 2023-24. The company recorded a net
profit of Rs.10.07 Lakhs for the Financial Year 2024-25 as against the net profit of Rs. 5.76 Lakhs for
the Previous Financial Year 2023-24

2. CHANGE IN THE NATURE OF THE BUSINESS, IF ANY

During the period under review and the date of Board's Report there was no change in the
nature of Business.

3. RESERVES

Pursuant to provisions of Section 134 (3) (j) of the Companies Act, 2013, the company has not
proposed to transfer any amount to general reserves account of the company during the year
under review.

However, the Closing balance of reserves, of the Company as at March 31st 2025 is Rs.
(1,14,52,398)

4. DIVIDEND

Keeping the Company's expansion and growth plans in mind, your directors have decided not
to recommend dividend for the Financial Year.

5. MATERIAL CHANGES & COMMITMENT AFFECTING THE FINANCIAL POSITION OF THE
COMPANY

There are no major material changes and commitments affecting the financial position of the
Company after the end of the financial year and up to date of this report.

6. BOARD MEETINGS

The Board of Directors duly met Five (4) times during the Financial Year from 1st April 2024 to
31st March 2025.

The dates on which the Board Meetings were held are 25.05.2024, 31-07.2024, 30.10.2024,
and 30-01-2025

7. APPOINTMENT / RE-APPOINTMENT / RESIGNATION / RETIREMENT OF DIRECTORS
/CEO/ CFO AND KEY MANANGERIAL PERSONNEL

A. Appointment of Directors:

As required under Regulation 36 (3) of the SEBI (LODR), Regulations, 2015, brief particulars of
the Directors seeking appointment/re-appointment are given as under:

Mr. Jason Jeorge (DIN: 00502736), Non-Executive Director, who retires by rotation and being
eligible offers himself for re-appointment.

Name of the Director

Mr. Jason Jeorge (DIN: 00502736)

Date of Birth

21/02/1965

Qualification

B.Sc Graduate from University of Calicut

Expertise in specific functional areas

He acquired expertise in Marketing strategies
which are very much essential for the success
of business activities of companies

Names of Listed entities in which the
person also holds the Directorship and
the membership of Committees of the
board and resigned in last three years

He is not holding any Directorship or
membership of Committee in any Listed
Company except Hindustan Bio Sciences
Limited.

Shareholding of non-executive
Directors/executive Directors.

66205 Equity Shares

Inter se relationship with any Director

Not related to other Directors

Mr. Shailendra Vyas was appointed as Company Secretary and Compliance Officer of the Company
with effect from 01-08-2025 appointed in the board meeting held on 31-07-2025.

Mr. Devanshu Dange was appointed as Company Secretary and Compliance Officer of the
Company with effect from 23rd April,2025 and resigned w.e.f closing of business hours 31-07-2025
due to his personal reasons and the Board place on its appreciation for the services rendered by him.

Mrs. Jyotna Sukavasi, Company secretary and Compliance Officer resigned with effect from
31.12.2024 due to personal reasons and the Board place on its appreciation for the services
rendered by her.

8. DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS

The Company has received declarations from Shri. Reji Abraham, B Nagireddy and G Prateek
Reddy Independent Directors of the Company to the effect that they are meeting the criteria of
independence as provided in Sub-Section (6) of Section 149 of the Companies Act, 2013 and
Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Independent Directors have also confirmed that they have complied with the Company's
Code of Conduct.

In terms of Regulations 25(8) of the Listing Regulations, the Independent Directors have
confirmed that they are not aware of any circumstance or situation, which exists or may be
reasonably anticipated, that could impair or impact their ability to discharge their duties with an
objective independent judgment and without any external influence.

FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS

Independent Directors are familiarized about the Company's operations and businesses.
Interaction with the Business heads and key executives of the Company is also facilitated.
Detailed presentations on important policies of the Company is also made to the directors.
Direct meetings with the Chairman are further facilitated to familiarize the incumbent Director
about the Company/its businesses and the group practices.

9. POLICY ON DIRECTOR’S APPOINTMENT AND REMUNERATION AND OTHER DETAILS

The assessment and appointment of Members to the Board is based on a combination of
criterion that includes ethics, personal and professional stature, domain expertise, gender
diversity and specific qualification required for the position. The potential Board Member is also
assessed on the basis of independence criteria defined in Section 149(6) of the Companies Act,
2013 and Regulation 27 of SEBI (LODR) Regulations, 2015.

In accordance with Section 178(3) of the Companies Act, 2013 and Regulation 19(4) of SEBI
(LODR) Regulations, 2015, on the recommendations of the Nomination and Remuneration
Committee, the Board adopted a remuneration policy for Directors, Key Management

Personnel (KMPs) and Senior Management. The Policy is attached a part of Corporate
Governance Report.

We affirm that the remuneration paid to the Directors is as per the terms laid down in the
Nomination and Remuneration Policy of the Company.

10. DIRECTORS’ RESPONSIBILITY STATEMENT

Pursuant to the requirement of Section 134(3)(c) and 134(5) of the Companies Act, 2013 and on
the basis of explanation given by the executives of the Company and subject to disclosures in
the Annual Accounts of the Company from time to time, we state as under:

1. That in the preparation of the annual accounts, the applicable accounting standards have been
followed along with proper explanation relating to material departures;

2. That the Directors have selected such accounting policies and applied them consistently and
made judgment and estimates that are reasonable and prudent so as to give a true and fair view
of the state of affairs of the Company at the end of the financial year and of the profit or loss of
the Company for that period;

3. That the Directors have taken proper and sufficient care for the maintenance of adequate
accounting records in accordance with the provisions of this Act for safeguarding the assets of
the Company and for preventing and detecting fraud and other irregularities;

4. That the Directors have prepared the annual accounts on a going concern basis:

5. That the Directors have lain down internal financial controls to be followed by the Company and
that such internal financial controls are adequate and are operating effectively; and

6. That the Directors have devised proper systems to ensure compliance with the provisions of all
applicable laws and that such systems are adequate and operating effectively.

11. INVESTOR EDUCTION AND PROTECTION FUND (IEPF)

Pursuant to the provisions of Section 124 of the Act, Investor Education and Protection Fund
Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 (“IEPF Rules”) read with the
relevant circulars and amendments thereto, the amount of dividend remaining unpaid or
unclaimed for a period of seven years from the due date is required to be transferred to the
Investor Education and Protection Fund (“IEPF”), constituted by the Central Government.

During the Year, no amount of dividend was unpaid or unclaimed for a period of seven years and
therefore no amount is required to be transferred to Investor Education and Provident Fund
under the Section 125(1) and Section 125(2) of the Act.

12. NAMES OF THE COMPANIES WHICH HAVE BECOME OR CEASED TO BE ITS
SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR

During the year, under review no Company has become or ceased to become its subsidiaries,
joint ventures or associate Company.

13. INFORMATION ABOUT THE FINANCIAL PERFORMANCE / FINANCIAL POSITION OF
THE SUBSIDIARIES / ASSOCIATES/ JOINT VENTURES

During the Financial Year under review, the Company does not have any subsidiaries, joint
ventures or associate Companies.

14. ANNUAL RETURN

As required pursuant to Section 92(3) of the Companies Act, 2013 and rule 12(1) of the
Companies (Management and Administration) Rules, 2014, an annual return in MGT-7 is
disclosed on the website of the company www.hindustanbiosciences.in

15. AUDITORS

a. Statutory Auditors

The members of the Company in accordance with Section 139 of the Companies Act, 2013
have passed a resolution for appointment of M/s. VASG & Associates, Chartered Accountants,
Hyderabad (FRN 006070S) as Statutory Auditors of the Company for a period of 5 years in the
30thAGM held on 30.09.2022 to hold office up to the conclusion of 35th Annual General
Meeting of the Company to be held in the year 2027.

Statutory Auditors Report

The Board has duly reviewed the Statutory Auditor's Report on the Accounts for the year ended
March 31, 2025 and has noted that the same does not have any reservation, qualification or
adverse remarks in the said report. However, the Board decided to further strengthen the
existing system and procedures to meet all kinds of challenges and growth in the coming years.

b. Secretarial Auditor

The Board of Directors of Company in accordance with Section 204 (3) of the Companies Act,
2013 have passed a resolution, subject to the approval of members in the ensuing Annual
General Meeting, for appointment of Mr.V.B.S.S.Prasad, Practicing Company Secretary (C.P.
No: 4605) held on 30.05.2025 to hold office up to the conclusion of 38th Annual General
Meeting of the Company to be held in the year 2030.

Secretarial Audit Report

The Board has duly reviewed the Secretarial Audit Report for the year ended March 31,2025 on
the Compliances according to the provisions of Section 204 of the Companies Act, 2013.

c. Cost Auditor

In terms of the provisions of Section 148 of the Companies Act, 2013, read with Rule 3 & 4 of The
Companies (Cost Record and Audit) Rules, 2014 and all other applicable provisions of the
Companies Act, 2013, the Cost Audit is not applicable to the Company.

d. Internal Auditor

The Company has appointed Mr. G.B.K Viswanadham as an Internal Auditor of the Company
for the Financial Year 2025-26.

16. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB SECTION
(12) OF SECTION 143 OTHER THAN THOSE WHICH ARE REPORTABLE TO THE
CENTRAL GOVERNMENT

There have been no frauds reported by the auditor's u/s 143(12).

17. INTERNAL AUDIT AND FINANCIAL CONTROLS

The Company has adequate internal controls consistent with the nature of business and size of
the operations, to effectively provide for safety of its assets, reliability of financial transactions
with adequate checks and balances, adherence to applicable statues, accounting policies,
approval procedures and to ensure optimum use of available resources. These systems are
reviewed and improved on a regular basis. It has a comprehensive budgetary control system to
monitor revenue and expenditure against approved budget on an ongoing basis.

18. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

The Company has not given loans, Guarantees or made any investments attracting the
provisions of Section 186 the Companies Act, 2013 during the year under review.

19. RELATED PARTY TRANSACTIONS

Company has formulated a policy on related party transactions which is also available on
Company's website. This policy deals with the review and approval of related party
transactions.

All related party transactions that were entered into during the financial year were on arm's
length basis and were in the ordinary course of business. There were no material significant
related party transactions made by the Company with the Promoters, Directors, Key
Managerial Personnel or the Senior Management which may have a potential conflict with the
interest of the Company at large.

Particulars of contracts or arrangements with related parties referred to in Section 188(1) of the
Companies Act, 2013 in the prescribed Form AOC-2 is appended as Annexure II which forms
part of this Report.

20. DISCLOSURE OF PARTICULARS WITH RESPECT TO CONSERVATION OF ENERGY,
TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The particulars as prescribed under Section 134(3) (m) of the Companies Act, 2013, read with
Companies (Accounts) Rules, 2014 are enclosed as Annexure III.

21. COMMITTEES

(I) . AUDIT COMMITTEE

The Audit Committee of the Company is constituted in line with the provisions of Regulation
18(1) of SEBI (LODR) Regulations read with Section 177 of the Companies Act, 2013 are
included in the Corporate Governance report, which forms part of this report.

(II) . NOMINATION AND REMUNERATION COMMITTEE

The Nomination and Remuneration Committee of the Company is constituted in line with the
provisions of Regulation 19(1) of SEBI (LODR) Regulations read with Section 178 of the
Companies Act, 2013 are included in the Corporate Governance report, which forms part of this
report.

(III) . STAKEHOLDERS RELATIONSHIP COMMITTEE

The Stakeholders Relationship Committee of the Company is constituted in line with the

provisions of Regulation 20 of SEBI (LODR) Regulations read with Section 178 of the
Companies Act, 2013 are included in the Corporate Governance report, which forms part of this
report.

22. VIGIL MECHANISM/WHISTLE BLOWER POLICY

In pursuant to the provisions of Section 177(9) & (10) of the Companies Act, 2013 read with
Regulation 22 of SEBI (LODR) Regulations, 2015, a vigil Mechanism for Directors and
employees to report genuine concerns has been established. It also provides for necessary
safeguards for protection against victimization for whistle blowing in good faith.

Vigil Mechanism Policy has been established by the Company for directors and employees to
report genuine concerns pursuant to the provisions of section 177(9) & (10) of the Companies
Act, 2013. The same has been placed on the website of the Company.

23 CORPORATE SOCIAL RESPONSIBILITY (CSR, COMPOSITION OF CSR COMMITTEE
AND CONTENTS OF CSR POLICY)

Section 135 of the Companies Act, 2013 provides the threshold limit for applicability of the CSR
to a Company i.e. (a) net worth of the Company to be Rs.500 Crore or more; or (b) turnover of
the company to be Rs.1,000 Crore or more; or (c) net profit of the company to be Rs.5 Crore or
more. As the Company does not fall under any of the threshold limits given above, the
provisions of section 135 are not applicable to the Company.

24. PUBLIC DEPOSITS

Your Company has not accepted any deposits falling within the meaning of Sec.73, 74 & 76 of
the Companies Act, 2013 read with the Rule 8(v) of Companies (Accounts) Rules 2014, during
the financial year under review.

25. SIGNIFICANT & MATERIAL ORDERS PASSED BY COURTS / REGULATORS /
TRIBUNALS

There are no significant and material orders passed by the regulators /courts that would impact
the going concern status of the Company and its future operations.

a. DISCLOSURE OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS

The Internal Financial Controls with reference to financial statements as designed and
implemented by the Company are adequate. The Company maintains appropriate system of
internal control, including monitoring procedures, to ensure that all assets are safeguarded
against loss from unauthorized use or disposition. Company policies, guidelines and
procedures provide for adequate checks and balances, and are meant to ensure that all
transactions are authorized, recorded and reported correctly.

During the period under review, there is no material or serious observations have been noticed
for inefficiency or inadequacy of such controls.

b. INSURANCE

The properties and assets of your Company are adequately insured.

c. CREDIT & GUARANTEE FACILITIES

The Company has not availed any Working Capital facilities and Term Loan from Banks during
the year under review.

d. SHARE CAPITAL

The authorized share capital of the Company stands at Rs.11,00,00,000/- divided into
5,50,00,000 equity shares of Rs.2/- each.

The paid-up share capital of the Company stands at Rs. 2,05,01,600/- divided into 1,02,50,800
equity shares of Rs.2/- each.

e. CORPORATE GOVERNANCE AND SHAREHOLDERS INFORMATION:

The Company has implemented all of its major stipulations as applicable to the Company. As
stipulated under Regulation 34 read with schedule V of SEBI (LODR) Regulations, 2015, a
report on Corporate Governance duly audited is appended as Annexure IV for information of the
Members. A requisite certificate from the Statutory Auditors of the Company confirming
compliance with the conditions of Corporate Governance is attached to the Report on
Corporate Governance.

f. MANAGEMENT DISCUSSIONS AND ANALYSIS REPORT:

The Management Discussion and Analysis Report, pursuant to Schedule V of SEBI (Listing
Obligation and Disclosure Requirements) Regulation, 2015 provides an overview of the affairs
of the Company, its legal status and autonomy, business environment, mission & objectives,
sectoral and segment-wise operational performance, strengths, opportunities, constraints,
strategy and risks and concerns, as well as human resource and internal control systems is
appended as Annexure V for information of the Members.

g. POLICIES:

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the
formulation of certain policies for all listed companies. All the policies are available on our
websitehttps://www.hindustanbiosciences.in/investors.html

h. ENVIRONMENTS AND HUMAN RESOURCE DEVELOPMENT:

Your Company always believes in keeping the environment pollution free and is fully committed
to its social responsibility. The Company has been taking upmost care in complying with all
pollution control measures from time to time strictly as per the directions of the Government.

We would like to place on record our appreciation for the efforts made by the management and
the keen interest shown by the Employees of your Company in this regard.

i. STATUTORY COMPLIANCE:

The Company has complied with the required provisions relating to statutory compliance with
regard to the affairs of the Company in all respects.

j. STATEMENT SHOWING THE NAMES OF THE TOP TEN EMPLOYEES IN TERMS OF
REMUNERATION DRAWN AND THE NAME OF EVERY EMPLOYEE AS PER RULE 5(2) &
(3) OF THE COMPANIES (APPOINTMENT & REMUNERATION) RULES, 2014:

A table containing the particulars in accordance with the provisions of Section 197(12) of the
Act, read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial
Personnel) Rules, 2014 is appended as Annexure VI (a) to this Report.

A statement showing the names of the top ten employees in terms of remuneration drawn and
the name of every employee is annexed to this Annual report as Annexure VI (b).

During the year, NONE of the employees is drawing a remuneration of Rs.1,02,00,000/- and
above per annum or Rs.8,50,000/- and above in aggregate per month, the limits specified under
the Section 197(12) of the Companies Act,2013 read with Rules 5(2) and 5(3) of the Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014.

k. RATIO OF REMUNERATION TO EACH DIRECTOR

Under section 197(12) of the Companies Act, 2013, and Rule 5(1) (2) & (3) of the Companies
(Appointment & Remuneration) Rules, 2014 read with Schedule V of the Companies Act, 2013
the ratio of remuneration of Managing Director (Mr.Venkata Rama Mohan Raju Jampana) to the
median remuneration of the employees is 1.81:1.00respectively.

l. CODE OF CONDUCT COMPLIANCE:

All Members of the Board and Senior Management have affirmed compliance to the Code of
Conduct for the Financial Year 2024-25. A declaration signed by the Managing Director
affirming compliance with the Company's Code of Conduct by the Board of Directors and Senior
Management for the Financial Year 2024-25 as required under Regulation 26(3) of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015 is included in the
Corporate Governance Report which is appended as Annexure VII' and forms part of this
Report.

m. MECHANISM FOR EVALUATION OF THE BOARD:

The Nomination and Remuneration Committee lays down the criteria for performance
evaluation of Independent Directors, Board of Directors and Committees of the Board.

The criteria for performance evaluation is based on the parameters like attendance and
participation at the meetings of the Board and Committees thereof, contribution to strategic
decision making, review of financial statements, business performance.

The evaluation of Board of Directors is performed by the Board after seeking all the inputs from
the Directors and the Board Committees by seeking inputs from the Committee members.

The performance evaluation of the individual directors is done by the Nomination and
Remuneration Committee.

The performance evaluation of non-independent directors, the Board as a whole and the
Chairman is done by a separate meeting of Independent Directors after taking inputs from the
Executive directors.

n. SECRETARIAL STANDARDS:

The Company is in compliance with the applicable secretarial standards.

o. EVENT BASED DISCLOSURES:

During the year under review, the Company has not taken up any of the following activities
except as mentioned:

1. Issue of sweat equity share: NA

2. Issue of shares with differential rights: NA

3. Issue of shares under employee's stock option scheme: NA

4. Disclosure on purchase by Company or giving of loans by it for purchase of its shares: NA

5. Buy back shares: NA

6. Disclosure about revision: NA

7. Preferential Allotment of Shares: NA

8. Reduction of Equity Share Capital: NA

p. CORPORATE INSOLVENCY RESOLUTION PROCESS INITIATED UNDER THE
INSOLVENCY AND BANKRUPTCY CODE, 2016 (IBC):

There is no application filed for corporate insolvency resolution process, by a financial or
operational creditor or by the company itself under the IBC before the NCLT.

q. CEO/ CFO CERTIFICATION:

The Managing Director and CFO certification of the financial statements for the year 2024-2025
is annexed in this Annual Report as Annexure VIII.

r. CODE OF CONDUCT FOR THE PREVENTION OF INSIDER TRADING:

The Board of Directors has adopted the Insider Trading Policy in accordance with the
requirements of the SEBI (Prohibition of Insider Trading) Regulation, 2015 and Amended
Regulations 2018. The Insider Trading Policy of the Company lays down guidelines and
procedures to be followed, and disclosures to be made while dealing with shares of the
Company, as well as the consequences of violation. The policy has been formulated to regulate,
monitor and ensure reporting of deals by employees and to maintain the highest ethical
standards of dealing in Company securities.

The Insider Trading Policy of the Company covering code of practices and procedures for fair
disclosure of unpublished price sensitive information and code of conduct for the prevention of
insider trading, is available on our website https://www.hindustanbiosciences.in

s. DETAILS OF APPLICATION MADE OR PROCEEDING PENDING UNDER INSOLVENCY
AND BANKRUPTCY CODE, 2016:

During the year under review, there were no applications made or proceedings pending in the
name of the Company under Insolvency and Bankruptcy Code, 2016.

t. DETAILS OF DIFFERENCE BETWEEN VALUATION AMOUNT ON ONE TIME
SETTLEMENT AND VALUATION WHILE AVAILING LOAN FROM BANKS AND FINANCIAL
INSTITUTIONS:

During the year under review, there has been no one time settlement of loans taken from banks
and financial institutions.

u. ACKNOWLEDGEMENTS:

Your directors wish to place on record their appreciation of the contribution made by the
employees at all levels, to the continued growth and prosperity of your Company. Your directors
also wish to place on record their appreciation of business constituents, banks and other
financial institutions and shareholders of the Company for their continued support for the
growth of the Company.

For and on behalf of the Board of Directors
Hindustan Bio Sciences Limited

Sd/-

Venkata Rama Mohan Raju Jampana

Place: Hyderabad Managing Director

Date:31-07-2025 (DIN: 00060800)


 
KYC IS ONE TIME EXERCISE WHILE DEALING IN SECURITIES MARKETS - ONCE KYC IS DONE THROUGH A SEBI REGISTERED INTERMEDIARY (BROKER, DP, MUTUAL FUND ETC.), YOU NEED NOT UNDERGO THE SAME PROCESS AGAIN WHEN YOU APPROACH ANOTHER INTERMEDIARY. | PREVENT UNAUTHORISED TRANSACTIONS IN YOUR ACCOUNT --> UPDATE YOUR MOBILE NUMBERS/EMAIL IDS WITH YOUR STOCK BROKER/DEPOSITORY PARTICIPANT. RECEIVE INFORMATION/ALERT OF YOUR TRANSACTIONS DIRECTLY FROM EXCHANGE/NSDL ON YOUR MOBILE/EMAIL AT THE END OF THE DAY .......... ISSUED IN THE INTEREST OF INVESTORS
Disclaimer Clause | Privacy | Terms of Use | Rules and regulations | Feedback| IG Redressal Mechanism | Investor Charter | Client Bank Accounts
Stocks A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others
MUTUAL FUND A B C D E F G H I J K L M N O P Q R S T U V W X Y Z OTHERS
Right and Obligation, RDD, Guidance Note in Vernacular Language
Attention Investors : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
  "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
  "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participants. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL on the same day.Issued in the interest of Investors."
Regd. Office: 76-77, Scindia House, 1st Floor, Janpath, Connaught Place, New Delhi – 110001
NSE CASH , NSE F&O,NSE CDS| BSE CASH ,BSE CDS |DP NSDL | MCX-SX SEBI NO: INZ000155732

Compliance Officer: Mukesh Rustagi, Company Secretary, Tel: 011-46890000, Email: mukesh_rustagi80@hotmail.com
For grievances please e-mail at: kkslig@hotmail.com

Important Links : NSE | BSE | MCX | SEBI | NSDL | Speed-e | CDSL | SCORES | NSDL E-voting | CDSL E-voting | SMART ODR | ODR CIRCULAR
 
Charts are powered by TradingView.
Copyrights @ 2014 © KK Securities Limited. All Right Reserved
Designed, developed and content provided by